| 000 | 01838 a2200589 4500 | ||
|---|---|---|---|
| 005 | 20250516053529.0 | ||
| 264 | 0 | _c20120508 | |
| 008 | 201205s 0 0 eng d | ||
| 022 | _a1476-5551 | ||
| 024 | 7 |
_a10.1038/leu.2011.234 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPlatzbecker, U | |
| 245 | 0 | 0 |
_aAzacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. _h[electronic resource] |
| 260 |
_bLeukemia _cMar 2012 |
||
| 300 |
_a381-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xadverse effects |
| 650 | 0 | 4 |
_aAzacitidine _xadverse effects |
| 650 | 0 | 4 | _aChimerism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xdrug therapy |
| 650 | 0 | 4 |
_aNeoplasm, Residual _xtherapy |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aWermke, M | |
| 700 | 1 | _aRadke, J | |
| 700 | 1 | _aOelschlaegel, U | |
| 700 | 1 | _aSeltmann, F | |
| 700 | 1 | _aKiani, A | |
| 700 | 1 | _aKlut, I-M | |
| 700 | 1 | _aKnoth, H | |
| 700 | 1 | _aRöllig, C | |
| 700 | 1 | _aSchetelig, J | |
| 700 | 1 | _aMohr, B | |
| 700 | 1 | _aGraehlert, X | |
| 700 | 1 | _aEhninger, G | |
| 700 | 1 | _aBornhäuser, M | |
| 700 | 1 | _aThiede, C | |
| 773 | 0 |
_tLeukemia _gvol. 26 _gno. 3 _gp. 381-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/leu.2011.234 _zAvailable from publisher's website |
| 999 |
_c21127926 _d21127926 |
||